-
EASL Featured New Voices丨Functional Cure of Chronic Hepatitis B: A Promising Journey
Chronic hepatitis B (CHB) remains a significant global health issue. At this year’s European Association for the Study of the Liver (EASL) Annual Meeting, the functional cure of CHB emerged as a focal point of research. “Hepatology Digest” had the privilege of speaking with Mr. Graham Griffiths, Chief Brand Officer at Barinthus Biotherapeutics, to gain…
-
EASL Voice of China丨Professor Yu Chen: Promising Prospects for HYX1 Liver Stem Cells in Treating Acute Liver Failure by Inhibiting Ferroptosis through Exosomes
Acute liver failure (ALF) is a severe liver injury caused by factors such as drugs, viruses, and ischemia-reperfusion injury, leading to massive hepatocyte apoptosis, necrosis, and potentially irreversible liver damage. The condition progresses rapidly, with high short-term mortality rates and poor prognosis, while medical treatment options are limited. Although liver transplantation is an effective strategy…
-
EASL Voice of China丨Professor Jian Sun: Correlation Between Serum HBV RNA and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) is a global public health issue, with hepatocellular carcinoma (HCC) being one of its most severe complications. Traditional viral markers have limited efficacy in predicting HCC risk, highlighting the need for new viral predictive indicators. On June 5, 2024, at the European Association for the Study of the Liver (EASL) annual…
-
EASL Express丨Latest Advances in Bulevirtide Treatment for Chronic Hepatitis D
Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B surface antigen (HBsAg) to replicate. Co-infection with HBV and HDV is considered the most severe form of chronic viral hepatitis, accelerating liver-related mortality and the development of hepatocellular carcinoma (HCC). At the 2024 European Association for the Study of the Liver (EASL)…
-
EASL Exclusive Interview丨Professor Jun Li: Comprehensive Research on Acute-on-Chronic Liver Failure from Pathogenesis to Clinical Treatment
Acute-on-chronic liver failure (ACLF) is a complex syndrome characterized by acute liver function deterioration based on chronic liver disease, accompanied by high mortality rates of liver and extra-hepatic organ failure. The short-term mortality rate of comprehensive internal medicine treatment ranges from 50% to 90%. Due to its high mortality and complex pathogenesis, research and treatment…
-
EASL China Voice丨Professor Shuangsuo Dang’s Team Showcases Three Achievements in Milan
From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy. During this event, the team led by Professor Shuangsuo Dang from the Department of Infectious Diseases at the Second Affiliated Hospital of Xi’an Jiaotong University presented three significant clinical and basic research findings:…
-
EASL Special Report丨Focus on the Management of Hepatitis B, Cirrhosis, and Portal Hypertension
Editor’s Note: From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. Over 7,000 hepatology experts from around the world gathered for this academic event. On the first day, the conference focused on various fields including chronic hepatitis B, cirrhosis, and portal hypertension. Hepatology…
-
EASL China Voice | Professors Jie Li, Julie Zhu, and Minghua Zheng: New Combined Non-Invasive Score Using PRO-C3 and GP73 Shows Significant Advantage in Assessing Liver Fibrosis in Chronic Hepatitis B
Liver biopsy is the “gold standard” for diagnosing liver fibrosis, but due to its high cost, invasive nature, and other disadvantages, it is not widely used. Currently, various non-invasive tests (NITs) based on serum biochemical indicators and/or imaging have been developed to evaluate liver stiffness and diagnose liver fibrosis, aiming to identify high-risk populations early…
Connecting Medical Expertise through Media